Strategies for Processing of Viral Vectors
To meet market needs for scalable and cost-effective manufacturing of viral vector systems, GE Healthcare Life Sciences is developing processes for the production of viral vectors.
The agenda will showcase start to finish production of adenovirus and highlight how similar strategies could be applied to other vectors.
Please join the event to learn more and get access to our experts’ best practices, knowledge, and experience on the process for scalable production of viral vectors.
09.45 Overview of the current industry challenges and opportunities Mats Lundgren, Customer Applications Director, GE Healthcare Life Sciences
10.00 Upstream Process Development for Viral Vectors: Case Study Adeno Virus Asa Hagner- McWhirter, Senior Scientist, GE Healthcare Life Sciences
10.45 Downstream Process Development for Viral Vectors: Case Study Adeno Virus Mats Lundgren, Customer Applications Director, GE Healthcare Life Sciences
11.15 Viral Vector Analysis Using Biacore John Sinfield, Field Application Specialist, GE Healthcare Life Sciences
12.00 Lunch and Networking
13.00 How fiber-based chromatography accelerates viral vector purifications Susana Brito dos Santos, R & D Scientist, Puridify, Part of GE Healthcare
13.45 Supporting Development of AAV Processes John Liddell, Chief Technologist, Centre for Process Innovation
15.00 Challenges and Strategies for LentiVirus Processing Vanja Misic, Scientist, Canadian Centre for Regenerative Medicine